News

Nearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year. Among the participants new to cytisinicline (prior attempt on placebo), 39% had quit at the end of the year. Participants were…

SEATTLE and VANCOUVER, British Columbia, September 28, 2026 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and…

CRL Cites Deficiencies at Third-Party Manufacturing Facility. No Efficacy or Clinical Safety Deficiencies Identified. SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) —Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today…

ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA. No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure. Nausea — a common barrier to treatment adherence with smoking cessation therapies — was reported in only 2.5% of participants over 52 weeks of…

Preclinical findings show cytisinicline’s minimal 5-HT3 serotonin receptor binding offers insight into observed low nausea rates in smoking and vaping cessation trials. SEATTLE and VANCOUVER, British Columbia, March 26, 2026 (GLOBENEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced the…